Summary
Alnylam Pharmaceuticals, Inc. announced its financial results for the third quarter ended September 30, 2022, on October 27, 2022. This 8-K filing primarily serves to furnish the press release detailing these results, which is crucial for investors seeking updates on the company's performance and financial standing. While the filing itself is brief, the attached press release (Exhibit 99.1) contains the substantive financial and operational information.
Key Highlights
- 1Alnylam Pharmaceuticals reported its third-quarter 2022 financial results on October 27, 2022.
- 2The primary purpose of this 8-K filing is to provide investors with access to the official press release containing the detailed financial and operational update.
- 3Investors should refer to the furnished press release (Exhibit 99.1) for specific details on revenue, expenses, net income/loss, and any other key financial metrics for the quarter.
- 4The filing clarifies that the information in Item 2.02 and its exhibits is furnished and not deemed 'filed' for certain regulatory purposes, a standard disclosure for such announcements.
- 5No new material events or significant business developments beyond the financial results announcement are detailed in the 8-K itself.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce and furnish Alnylam Pharmaceuticals' financial results for the quarter ended September 30, 2022, by including the full press release (Exhibit 99.1).
All specific financial details, including revenue, net income/loss, and other key performance indicators for the quarter ended September 30, 2022, can be found in the press release furnished as Exhibit 99.1 to this 8-K filing.
No, the information provided in Item 2.02 of this 8-K, including the press release, is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act or incorporated by reference into other SEC filings, unless expressly stated otherwise in a specific filing.